In order to circunvent problems of physico-chemical stablity in biological media and to get the benefits of lipids as carries of drugs, new formulations contaning solid lipid nanoparticles, SLN have been investigated since the 90 years. The main characteristics of the dispersions of SLN are the strong interaction with the incorporated drugs , the sustained release and the specific targeting to the therapeutic site. The consequence of that is the higher efficacy of action. A second generation of lipid nanoparticles are the nanostructured lipid carries, NLC. The main difference between SLN and NLC is the inclusion of liquid lipids added to solid lipids in the matrix of NLC. Therefore, the NLC have a less ordered matrix containing no perfect crystals. In consequence of that, NLC are able to load a higher amount of drug and to prevent its expulsion during storage. Additionally, the pattern of drug delivery may be modulated. The cancer of uterus colon is the third main cause of death in women in the world, causing about 200.000 death per year. The data of the literature show a clear relationship between the infection by the HPV virus and the development of uterus cancer. The proteins E5, E6 e E7 are exclusively present in the tumor cells induced by HPV . Therefore they represent important targeting to a profilatic or therapeutic vaccine against that tumors. So, a antigen-specific immunotherapy against cancer appear as an promising strategy to the control of this kind of tumor. The induction of the immune response against the onco-proteins of the HPV-16, mediated for TCD8 cytotoxic specific linfocites may be an important alternative for studies. Vaccines containing the antitumor antigen E7 incorporated in NLS or SLN represent an promising strategy for the generation of a specific-antigen immune response due to the easily of manufacture , stability, safety and possibilities for administration in repetitive doses by parenteral route. In this context, the objective of the present project is the production of SLN and NLC incorporating the tumor antigen E7 or its respective immunogenic peptides for parenteral administration and evaluation of the immunotherapeutic response against tumors induced by HPV.
News published in Agência FAPESP Newsletter about the scholarship: